{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T18:52:58Z","timestamp":1790103178934,"version":"4.0.1"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T00:00:00Z","timestamp":1594684800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.ctrv.2020.102069","type":"journal-article","created":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T12:31:59Z","timestamp":1594816319000},"page":"102069","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"special_numbering":"C","title":["Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review"],"prefix":"10.1016","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0269-5849","authenticated-orcid":false,"given":"M.J.M.","family":"Uijen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4935-6206","authenticated-orcid":false,"given":"G.","family":"Lassche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.C.H.","family":"van Engen-van Grunsven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0159-8660","authenticated-orcid":false,"given":"Y.","family":"Tada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.W.","family":"Verhaegh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.","family":"Schalken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.M.L.","family":"Driessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.M.L.","family":"van Herpen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2020.102069_b0005","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/BF00301495","article-title":"Salivary duct carcinoma. A group of salivary gland tumors analogous to mammary duct carcinoma","volume":"192","author":"Kleinsasser","year":"1968","journal-title":"Arch Klin Exp Ohren Nasen Kehlkopfheilkd"},{"key":"10.1016\/j.ctrv.2020.102069_b0010","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/ijc.31353","article-title":"A clinicopathological study and prognostic factor analysis of 177 salivary duct carcinoma patients from The Netherlands","volume":"143","author":"Boon","year":"2018","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2020.102069_b0015","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1001\/jamaoto.2015.3930","article-title":"A 20-Year Review of 75 Cases of Salivary Duct Carcinoma","volume":"142","author":"Gilbert","year":"2016","journal-title":"JAMA Otolaryngol\u2013 Head Neck Surg"},{"key":"10.1016\/j.ctrv.2020.102069_b0020","unstructured":"El-Naggar AK CJ, Grandis JR, Takata T, Slootweg PJ, eds. WHO classification of head and neck tumours, 4th ed.: World Health Organization (IARC); 2017."},{"key":"10.1016\/j.ctrv.2020.102069_b0025","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.oraloncology.2011.04.020","article-title":"Salivary gland carcinoma in Denmark 1990\u20132005: a national study of incidence, site and histology. Results of the Danish Head and Neck Cancer Group (DAHANCA)","volume":"47","author":"Bjorndal","year":"2011","journal-title":"Oral Oncol"},{"key":"10.1016\/j.ctrv.2020.102069_b0030","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.5858\/133.11.1763","article-title":"Update on selected salivary gland neoplasms","volume":"133","author":"McHugh","year":"2009","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.ctrv.2020.102069_b0035","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/00016480510003174","article-title":"Salivary gland cancer in Finland 1991\u201396: an evaluation of 237 cases","volume":"125","author":"Luukkaa","year":"2005","journal-title":"Acta Otolaryngol"},{"key":"10.1016\/j.ctrv.2020.102069_b0040","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1016\/j.oraloncology.2014.08.010","article-title":"Prognostic factors and oncologic outcomes of 56 salivary duct carcinoma patients in a single institution: high rate of systemic failure warrants targeted therapy","volume":"50","author":"Roh","year":"2014","journal-title":"Oral Oncol"},{"key":"10.1016\/j.ctrv.2020.102069_b0045","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/hed.23350","article-title":"Survival rates and prognostic factors for infiltrating salivary duct carcinoma: Analysis of 228 cases from the Surveillance, Epidemiology, and End Results database","volume":"36","author":"Jayaprakash","year":"2014","journal-title":"Head Neck"},{"key":"10.1016\/j.ctrv.2020.102069_b0050","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/hed.25194","article-title":"Salivary duct carcinoma: Prospective multicenter study of 61 cases of the Reseau d'Expertise Francais des Cancers ORL Rares","volume":"41","author":"Villepelet","year":"2019","journal-title":"Head Neck"},{"issue":"Suppl 1","key":"10.1016\/j.ctrv.2020.102069_b0055","first-page":"E820","article-title":"Salivary duct carcinoma: Treatment, outcomes, and patterns of failure","volume":"38","author":"Johnston","year":"2016","journal-title":"Head Neck"},{"key":"10.1016\/j.ctrv.2020.102069_b0060","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/hed.25035","article-title":"Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The Netherlands","volume":"40","author":"Boon","year":"2018","journal-title":"Head Neck"},{"key":"10.1016\/j.ctrv.2020.102069_b0065","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.oraloncology.2017.09.008","article-title":"Salivary duct carcinoma: An aggressive salivary gland malignancy with opportunities for targeted therapy","volume":"74","author":"Schmitt","year":"2017","journal-title":"Oral Oncol"},{"key":"10.1016\/j.ctrv.2020.102069_b0070","doi-asserted-by":"crossref","first-page":"59023","DOI":"10.18632\/oncotarget.19812","article-title":"Biomarker immunoprofile in salivary duct carcinomas: clinicopathological and prognostic implications with evaluation of the revised classification","volume":"8","author":"Takase","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2020.102069_b0075","article-title":"Prognostic and histogenetic roles of gene alteration and the expression of key potentially actionable targets in salivary duct carcinomas","author":"Shimura","year":"20179","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2020.102069_b0080","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.1158\/1078-0432.CCR-16-0637","article-title":"Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer","volume":"22","author":"Dalin","year":"2016","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.ctrv.2020.102069_b0085","doi-asserted-by":"crossref","first-page":"12724","DOI":"10.1038\/s41598-019-49215-9","article-title":"The expression of PD-L1 in salivary gland carcinomas","volume":"9","author":"Vital","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.ctrv.2020.102069_b0090","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/his.13944","article-title":"The immune microenvironment and expression of PD-L1, PD-1, PRAME and MHC I in salivary duct carcinoma","volume":"75","author":"Xu","year":"2019","journal-title":"Histopathology"},{"key":"10.1016\/j.ctrv.2020.102069_b0095","article-title":"Developing methodology for the creation of clinical practice guidelines for rare diseases: A report from RARE-Bestpractices","volume":"3","author":"Pai","year":"2015","journal-title":"Rare Dis"},{"key":"10.1016\/j.ctrv.2020.102069_b0100","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ctrv.2020.102069_b0105","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.2007.11.8612","article-title":"Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and\/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands","volume":"25","author":"Agulnik","year":"2007","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102069_b0110","first-page":"1","article-title":"Sequential HER2-Targeted Therapy in Salivary Ductal Carcinoma With HER2\/neu Overexpression and a Concomitant ERBB2 Mutation. JCO Precision","author":"Almquist","year":"2018","journal-title":"Oncology"},{"key":"10.1016\/j.ctrv.2020.102069_b0115","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1159\/000488669","article-title":"Second-Line Treatment of HER2-Positive Salivary Gland Tumor: Ado-Trastuzumab Emtansine (T-DM1) after Progression on Trastuzumab","volume":"11","author":"Correa","year":"2018","journal-title":"Case Reports Oncol"},{"key":"10.1016\/j.ctrv.2020.102069_b0120","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1080\/17843286.2016.1173940","article-title":"Metastatic HER-2-positive salivary gland carcinoma treated with trastuzumab and a taxane: a series of six patients","volume":"71","author":"De Block","year":"2016","journal-title":"Acta Clin Belg"},{"key":"10.1016\/j.ctrv.2020.102069_b0125","first-page":"22463","article-title":"Metastatic salivary ductal carcinoma androgen receptor-positive with V600E BRAF gene mutation","volume":"9","author":"de Cecio","year":"2016","journal-title":"Int J Clin Exp Med"},{"key":"10.1016\/j.ctrv.2020.102069_b0130","doi-asserted-by":"crossref","first-page":"E985","DOI":"10.1503\/cmaj.180286","article-title":"Androgen deprivation therapy for metastatic salivary gland cancer","volume":"190","author":"Elkrief","year":"2018","journal-title":"CMAJ"},{"key":"10.1016\/j.ctrv.2020.102069_b0135","doi-asserted-by":"crossref","first-page":"E25","DOI":"10.1002\/hed.23429","article-title":"Human epidermal receptor 2-amplified salivary duct carcinoma: regression with dual human epidermal receptor 2 inhibition and anti-vascular endothelial growth factor combination treatment","volume":"36","author":"Falchook","year":"2014","journal-title":"Head Neck"},{"issue":"4","key":"10.1016\/j.ctrv.2020.102069_b0140","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2018-000381","article-title":"Phase i study of TrasGEX, a glyco-optimised anti-HER2 monoclonal antibody, in patients with HER2-positive solid tumours","volume":"3","author":"Fiedler","year":"2018","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctrv.2020.102069_b0145","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/annonc\/mdx771","article-title":"A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma","volume":"29","author":"Fushimi","year":"2018","journal-title":"Ann Oncol: Off J Eur Med Oncol"},{"key":"10.1016\/j.ctrv.2020.102069_b0150","first-page":"111","article-title":"Targeted therapy with trastuzumab for epidermal growth factor receptor 2 (HER2)-positive advanced salivary duct carcinoma: A case report","volume":"11","author":"Gibo","year":"2019","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102069_b0155","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.12788\/jcso.0419","article-title":"Salivary ductal adenocarcinoma with complete response to androgen blockade","volume":"16","author":"Graham","year":"2018","journal-title":"J Community Support Oncol"},{"key":"10.1016\/j.ctrv.2020.102069_b0160","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","article-title":"Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations","volume":"373","author":"Hyman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2020.102069_b0165","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/hed.23647","article-title":"Phase II study of gefitinib in patients with advanced salivary gland cancers","volume":"37","author":"Jakob","year":"2015","journal-title":"Head Neck"},{"key":"10.1016\/j.ctrv.2020.102069_b0170","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1159\/000355219","article-title":"Complete Response to Trastuzumab-Based Chemotherapy in a Patient with Human Epidermal Growth Factor Receptor-2-Positive Metastatic Salivary Duct Carcinoma ex Pleomorphic Adenoma","volume":"6","author":"Kadowaki","year":"2013","journal-title":"Case Reports Oncol"},{"key":"10.1016\/j.ctrv.2020.102069_b0175","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1007\/s12032-011-9884-1","article-title":"Targeted therapy with trastuzumab for advanced salivary ductal carcinoma: case report and literature review","volume":"29","author":"Kaidar-Person","year":"2012","journal-title":"Med Oncol (Northwood, London, England)"},{"key":"10.1016\/j.ctrv.2020.102069_b0180","doi-asserted-by":"crossref","first-page":"886","DOI":"10.3892\/mco.2017.1226","article-title":"Salivary duct carcinoma treated with cetuximab-based targeted therapy: A case report","volume":"6","author":"Kawahara","year":"2017","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102069_b0185","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1002\/cncr.30537","article-title":"Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01)","volume":"123","author":"Kim","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2020.102069_b0190","doi-asserted-by":"crossref","first-page":"E372","DOI":"10.1002\/hed.23307","article-title":"Salivary duct carcinoma responding to trastuzumab-based therapy: case report and review of the literature","volume":"35","author":"Krishnamurthy","year":"2013","journal-title":"Head Neck"},{"key":"10.1016\/j.ctrv.2020.102069_b0195","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/cncr.24745","article-title":"A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer: a trial of the NCIC Clinical Trials Group","volume":"116","author":"Laurie","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2020.102069_b0200","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.joms.2013.11.014","article-title":"Salivary duct carcinoma of the parotid gland: Is adjuvant HER-2-targeted therapy required?","volume":"72","author":"Lee","year":"2014","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.ctrv.2020.102069_b0205","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1093\/oxfordjournals.annonc.a010684","article-title":"Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase II trial of 22 patients","volume":"7","author":"Licitra","year":"1996","journal-title":"Ann Oncol: Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ctrv.2020.102069_b0210","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1634\/theoncologist.2012-0369","article-title":"Trastuzumab for the treatment of salivary duct carcinoma","volume":"18","author":"Limaye","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2020.102069_b0215","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.6004\/jnccn.2018.7056","article-title":"First-Line Treatment of Widely Metastatic BRAF-Mutated Salivary Duct Carcinoma With Combined BRAF and MEK Inhibition","volume":"16","author":"Lin","year":"2018","journal-title":"J Natl Comprehensive Cancer Netw: JNCCN"},{"key":"10.1016\/j.ctrv.2020.102069_b0220","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ejca.2016.09.022","article-title":"A phase II study of sorafenib in recurrent and\/or metastatic salivary gland carcinomas: Translational analyses and clinical impact","volume":"69","author":"Locati","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2020.102069_b0225","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1002\/hed.23940","article-title":"Clinical activity of androgen deprivation therapy in patients with metastatic\/relapsed androgen receptor-positive salivary gland cancers","volume":"38","author":"Locati","year":"2016","journal-title":"Head Neck"},{"key":"10.1016\/j.ctrv.2020.102069_b0230","doi-asserted-by":"crossref","first-page":"948","DOI":"10.3109\/00016489.2016.1170876","article-title":"Combination chemotherapy of carboplatin and paclitaxel for advanced\/metastatic salivary gland carcinoma patients: differences in responses by different pathological diagnoses","volume":"136","author":"Nakano","year":"2016","journal-title":"Acta Otolaryngol"},{"key":"10.1016\/j.ctrv.2020.102069_b0235","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1158\/1078-0432.CCR-12-1842","article-title":"Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment","volume":"19","author":"Nardi","year":"2013","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.ctrv.2020.102069_b0240","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1017\/S0022215108002314","article-title":"Biological therapy of salivary duct carcinoma","volume":"123","author":"Nashed","year":"2009","journal-title":"J Laryngol Otol"},{"key":"10.1016\/j.ctrv.2020.102069_b0245","doi-asserted-by":"crossref","first-page":"843","DOI":"10.21873\/invivo.11549","article-title":"Carboplatin and docetaxel in patients with salivary gland carcinoma: A retrospective study","volume":"33","author":"Okada","year":"2019","journal-title":"Vivo"},{"key":"10.1016\/j.ctrv.2020.102069_b0250","doi-asserted-by":"crossref","first-page":"E100","DOI":"10.1002\/hed.25392","article-title":"Exceptional responses to pertuzumab, trastuzumab, and docetaxel in human epidermal growth factor receptor-2 high expressing salivary duct carcinomas","volume":"40","author":"Park","year":"2018","journal-title":"Head Neck"},{"key":"10.1016\/j.ctrv.2020.102069_b0255","doi-asserted-by":"crossref","first-page":"e727","DOI":"10.1200\/JCO.2011.36.2095","article-title":"Salivary duct carcinoma: targeting the phosphatidylinositol 3-kinase pathway by blocking mammalian target of rapamycin with temsirolimus","volume":"29","author":"Piha-Paul","year":"2011","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102069_b0260","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1002\/hed.20714","article-title":"Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab-based therapy","volume":"30","author":"Prat","year":"2008","journal-title":"Head Neck"},{"issue":"3","key":"10.1016\/j.ctrv.2020.102069_b0265","first-page":"1","article-title":"Targeting HER2\/neu Oncogene Overexpression With Ado-Trastuzumab Emtansine in the Treatment of Metastatic Salivary Gland Neoplasms: A Single-Institution Experience","author":"Swed","year":"2019","journal-title":"JCO Precision Oncol"},{"key":"10.1016\/j.ctrv.2020.102069_b0270","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1200\/JCO.18.00545","article-title":"Phase II Trial of Trastuzumab and Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Salivary Duct Carcinoma","volume":"37","author":"Takahashi","year":"2019","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102069_b0275","doi-asserted-by":"crossref","first-page":"E40","DOI":"10.1002\/hed.24634","article-title":"Significant and durable clinical benefit from trastuzumab in 2 patients with HER2-amplified salivary gland cancer and a review of the literature","volume":"39","author":"Thorpe","year":"2017","journal-title":"Head Neck"},{"key":"10.1016\/j.ctrv.2020.102069_b0280","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s13691-016-0247-9","article-title":"Pathological response of salivary duct carcinoma to trastuzumab and docetaxel therapy","volume":"5","author":"Ueki","year":"2016","journal-title":"Int Cancer Conf J"},{"key":"10.1016\/j.ctrv.2020.102069_b0285","doi-asserted-by":"crossref","first-page":"288","DOI":"10.6004\/jnccn.2015.0040","article-title":"Abiraterone in metastatic salivary duct carcinoma","volume":"13","author":"Urban","year":"2015","journal-title":"J Natl Comprehensive Cancer Netw: JNCCN"},{"key":"10.1016\/j.ctrv.2020.102069_b0290","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.oraloncology.2017.06.023","article-title":"Combination of docetaxel, trastuzumab and pertuzumab or treatment with trastuzumab-emtansine for metastatic salivary duct carcinoma","volume":"72","author":"van Boxtel","year":"2017","journal-title":"Oral Oncol"},{"key":"10.1016\/j.ctrv.2020.102069_b0295","doi-asserted-by":"crossref","first-page":"701","DOI":"10.3389\/fonc.2019.00701","article-title":"First Line Androgen Deprivation Therapy vs Chemotherapy for Patients With Androgen Receptor Positive Recurrent or Metastatic Salivary Gland Carcinoma-A Retrospective Study","volume":"9","author":"Viscuse","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2020.102069_b0300","doi-asserted-by":"crossref","first-page":"6061","DOI":"10.1158\/1078-0432.CCR-15-2568","article-title":"Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations","volume":"22","author":"Wang","year":"2016","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.ctrv.2020.102069_b0305","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1440-1827.2008.02231.x","article-title":"Aggressive invasive micropapillary salivary duct carcinoma of the parotid gland","volume":"58","author":"Yamamoto","year":"2008","journal-title":"Pathol Int"},{"key":"10.1016\/j.ctrv.2020.102069_b0310","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.amjoto.2014.07.007","article-title":"Clinicopathologic study of salivary duct carcinoma and the efficacy of androgen deprivation therapy","volume":"35","author":"Yamamoto","year":"2014","journal-title":"Am J Otolaryngol"},{"key":"10.1016\/j.ctrv.2020.102069_b0315","first-page":"627","article-title":"Effective treatment by both anti-androgen therapy and chemotherapy for a patient with advanced salivary duct carcinoma","volume":"38","author":"Kuroda","year":"2011","journal-title":"Gan To Kagaku Ryoho"},{"key":"10.1016\/j.ctrv.2020.102069_b0320","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.3950\/jibiinkoka.117.1108","article-title":"A case of metastatic salivary duct carcinoma successfully treated with trastuzumab-based targeted therapy","volume":"117","author":"Iguchi","year":"2014","journal-title":"Nihon Jibiinkoka Gakkai Kaiho"},{"key":"10.1016\/j.ctrv.2020.102069_b0325","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.oraloncology.2016.12.016","article-title":"Systemic therapy in metastatic salivary gland carcinomas: A pathology-driven paradigm?","volume":"66","author":"Alfieri","year":"2017","journal-title":"Oral Oncol"},{"key":"10.1016\/j.ctrv.2020.102069_b0330","first-page":"19-","article-title":"Systemic therapy in the management of metastatic or advanced salivary gland cancers. Head Neck","volume":"4","author":"Lagha","year":"2012","journal-title":"Oncol"},{"key":"10.1016\/j.ctrv.2020.102069_b0335","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1200\/JCO.2005.05.3025","article-title":"Systemic therapy in the palliative management of advanced salivary gland cancers","volume":"24","author":"Laurie","year":"2006","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.ctrv.2020.102069_b0340","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/s12105-017-0798-x","article-title":"Salivary Duct Carcinoma: An Update on Morphologic Mimics and Diagnostic Use of Androgen Receptor Immunohistochemistry","volume":"11","author":"Udager","year":"2017","journal-title":"Head Neck Pathol"},{"key":"10.1016\/j.ctrv.2020.102069_b0345","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ctrv.2020.102069_b0350","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jama.294.2.238","article-title":"Androgen deprivation therapy for prostate cancer","volume":"294","author":"Sharifi","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.ctrv.2020.102069_b0355","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","article-title":"Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer","volume":"71","author":"Cornford","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctrv.2020.102069_b0360","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1002\/cncr.24395","article-title":"Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival","volume":"115","author":"Akaza","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2020.102069_b0365","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/(SICI)1097-0045(19980101)34:1<61::AID-PROS8>3.0.CO;2-N","article-title":"Bicalutamide (Casodex) in the treatment of prostate cancer: history of clinical development","volume":"34","author":"Kolvenbag","year":"1998","journal-title":"Prostate"},{"key":"10.1016\/j.ctrv.2020.102069_b0370","doi-asserted-by":"crossref","first-page":"858","DOI":"10.3389\/fonc.2019.00858","article-title":"Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer","volume":"9","author":"Feng","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2020.102069_b0375","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2020.102069_b0380","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1113216","article-title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ctrv.2020.102069_b0385","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1056\/NEJMoa1413513","article-title":"Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer","volume":"372","author":"Swain","year":"2015","journal-title":"New Engl J Med"},{"issue":"110","key":"10.1016\/j.ctrv.2020.102069_b0390","first-page":"62","article-title":"Adjuvant androgen deprivation therapy for poor-risk, androgen receptor-positive salivary duct carcinoma","volume":"2019","author":"van Boxtel","year":"1990","journal-title":"Eur J Cancer (Oxford, England)"},{"key":"10.1016\/j.ctrv.2020.102069_b0395","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.5858\/134.7.e48","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version)","volume":"134","author":"Hammond","year":"2010","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.ctrv.2020.102069_b0400","article-title":"Prediction of clinical benefit from androgen deprivation therapy in salivary duct carcinoma patients","author":"van Boxtel","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2020.102069_b0405","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update","volume":"36","author":"Wolff","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102069_b0410","first-page":"Cd006242","article-title":"Trastuzumab-containing regimens for metastatic breast cancer","volume":"2014","author":"Balduzzi","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ctrv.2020.102069_b0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2019.101906","article-title":"Advances and challenges in precision medicine in salivary gland cancer","volume":"80","author":"Lassche","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2020.102069_b0420","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.eururo.2014.07.010","article-title":"Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them","volume":"67","author":"Nguyen","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctrv.2020.102069_b0425","doi-asserted-by":"crossref","first-page":"6001-","DOI":"10.1200\/JCO.2019.37.15_suppl.6001","article-title":"Ado-trastuzumab emtansine in patients with HER2 amplified salivary gland cancers (SGCs): Results from a phase II basket trial","volume":"37","author":"Li","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102069_b0430","doi-asserted-by":"crossref","first-page":"688-701","DOI":"10.1158\/2159-8290.CD-19-1014","article-title":"Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors","volume":"10","author":"Tsurutani","year":"2020","journal-title":"Cancer Discovery"},{"key":"10.1016\/j.ctrv.2020.102069_b0435","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-16-0637","article-title":"Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer","author":"Dalin","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"15_suppl","key":"10.1016\/j.ctrv.2020.102069_b0440","doi-asserted-by":"crossref","first-page":"6504","DOI":"10.1200\/JCO.2020.38.15_suppl.6504","article-title":"Preliminary activity of tipifarnib in tumors of the head and neck, salivary gland and urothelial tract with HRAS mutations.","volume":"38","author":"Ho","year":"2020","journal-title":"JCO"},{"key":"10.1016\/j.ctrv.2020.102069_b0445","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer","volume":"380","author":"Andr\u00e9","year":"2019","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ctrv.2020.102069_b0450","article-title":"The immune microenvironment and neoantigen landscape of aggressive salivary gland carcinomas differ by subtype","author":"Morris","year":"2020","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737220301079?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737220301079?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:23:18Z","timestamp":1759656198000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737220301079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":90,"alternative-id":["S0305737220301079"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2020.102069","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2020.102069","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102069"}}